Reprogramming Rotavirus: Reverse Genetics-Driven Design of Viral Vector Platforms.

Ke Li, Xiao Wei, Xuanze Ouyang, Xiafei Liu, Pengdi Chai, Yu Bai, Zhaojun Duan

Abstract readReview

In one paragraph

Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ke LiNHC Key Laboratory of Medical Virology and Viral Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

Xiao WeiNHC Key Laboratory of Medical Virology and Viral Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

Xuanze OuyangNHC Key Laboratory of Medical Virology and Viral Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

Xiafei LiuThe First Clinical Medical Institute, Henan University of Chinese Medicine, Zhengzhou 450000, China.

Pengdi ChaiNHC Key Laboratory of Medical Virology and Viral Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.ORCID 0009-0002-1995-6021

Yu BaiCenter for Drug Evaluation, National Medical Products Administration, Beijing 100163, China.

Zhaojun DuanNHC Key Laboratory of Medical Virology and Viral Disease, National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.ORCID 0000-0003-3090-4150

Funding

National Natural Science Foundation of China No. 82402625

6 · The paper itself

Abstract

Rotaviruses remain the leading cause of severe dehydrating diarrhea and associated mortality in children under five years of age worldwide. The successful global rollout of live-attenuated oral rotavirus vaccines has dramatically reduced rotavirus gastroenteritis morbidity and mortality, unequivocally demonstrating their excellent safety profile and potent induction of mucosal immunity. These attributes highlight the substantial potential of rotaviruses as novel oral mucosal vaccine vectors. Recent breakthroughs in reverse genetics, particularly the establishment of a fully plasmid-based system in 2017, have enabled precise insertion and stable expression of foreign antigens at targeted genomic loci. This advance has opened a viable pathway for developing multivalent oral mucosal vaccines. This review traces the historical development of rotavirus reverse genetics and summarizes the latest progress in its application as a vaccine vector platform. We focus on key strategies for foreign gene insertion and immunological outcomes in animal models, while critically evaluating persistent challenges-virus rescue efficiency, genetic stability of inserts, and limitations of current animal models-and outlining the rational design framework for RV-based vectors with improved stability, expression efficiency, and immunogenicity.

Indexed as

Genetic VectorsReverse GeneticsRotavirusRotavirus InfectionsRotavirus VaccinesAnimalsHumansImmunity, MucosalVaccines, AttenuatedRotavirus VaccinesVaccines, Attenuatedoral mucosal vaccinereverse geneticsrotavirusvaccine vector

Identifiers

PMID42357665

DOI10.3390/v18060655

PMCPMC13307774

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.